<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03202186</url>
  </required_header>
  <id_info>
    <org_study_id>BHR-401-301</org_study_id>
    <nct_id>NCT03202186</nct_id>
  </id_info>
  <brief_title>Study of Progesterone in Treatment of Vasomotor Symptoms</brief_title>
  <acronym>PROGEST</acronym>
  <official_title>Double-Blind Trial Investigating the Efficacy of Different Doses of Progesterone Compared With Placebo for Treatment of Vasomotor Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BHR Pharma, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BHR Pharma, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the clinical trial is to demonstrate superiority of BHR401 (oral&#xD;
      micronized progesterone) versus placebo as a monotherapy for moderate to severe VMS in&#xD;
      postmenopausal women. Three different doses of BHR-401 (200 mg, 300 mg or 400 mg) will be&#xD;
      tested against placebo in hierarchical order, starting with the highest dose. Superiority&#xD;
      will be defined as a significant (significance level α = 0.05) reduction of moderate to&#xD;
      severe VMS frequency compared to placebo at treatment week 12 (the primary efficacy endpoint&#xD;
      of the study).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Inability to recruit subjects&#xD;
  </why_stopped>
  <start_date type="Actual">August 1, 2017</start_date>
  <completion_date type="Actual">December 6, 2018</completion_date>
  <primary_completion_date type="Actual">December 6, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Placebo controlled parallel arm study for 12 weeks</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Double blind, placebo controlled</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of moderate to severe vasomotor symptoms at 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>the change vs. baseline of the frequency of moderate or severe VMS episodes (per day) after 12 weeks of treatment with BHR-401or placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of moderate to severe vasomotor symptoms at 4 weeks</measure>
    <time_frame>4 weeks</time_frame>
    <description>the change vs. baseline of the frequency of moderate or severe VMS episodes (per day)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of vasomotor symptoms at 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>the change vs. baseline of the secerity of moderate or severe VMS episodes (per day)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of vasomotor symptoms at 4 weeks</measure>
    <time_frame>4 weeks</time_frame>
    <description>the change vs. baseline of the severity of moderate or severe VMS episodes (per day)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kupperman Index</measure>
    <time_frame>4 and 12 weeks</time_frame>
    <description>Change vs. baseline of postmenopausal symptoms as assessed by the physician by means of the Kupperman Index inventory after 4 weeks and 12 weeks of treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>Sleep quality assessed by means of the Pittsburgh Sleep Quality Index (PSQI)</measure>
    <time_frame>4 and 12 weeks</time_frame>
    <description>Change in subjective sleep quality vs. baseline as assessed by means of the Pittsburgh Sleep Quality Index (PSQI) after 4 weeks and 12 weeks of treatment</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Menopause Related Conditions</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>oral administration of Placebo capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Progesterone 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral administration of progesterone 200 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Progesterone 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral administration of progesterone 300 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Progesterone 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral administration of progesterone 400 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone oral capsule</intervention_name>
    <description>Oral capsule treatment</description>
    <arm_group_label>Progesterone 200 mg</arm_group_label>
    <arm_group_label>Progesterone 300 mg</arm_group_label>
    <arm_group_label>Progesterone 400 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Oral capsule treatment</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing and able to provide written informed consent&#xD;
&#xD;
          -  Adult (≥ 18 years), postmenopausal women, where postmenopause is defined as&#xD;
&#xD;
               -  at least 12 months of spontaneous amenorrhea, or&#xD;
&#xD;
               -  6 months of spontaneous amenorrhea and follicle stimulating hormone (FSH) levels&#xD;
                  &gt; 40 mIU/ml, or&#xD;
&#xD;
               -  status at least 6 weeks after bilateral oophorectomy with or without hysterectomy&#xD;
&#xD;
          -  Non-smoker&#xD;
&#xD;
          -  Mammography without pathological findings obtained within routine medical care no&#xD;
             longer than 12 months prior to screening visit&#xD;
&#xD;
          -  Cervical smear (Papanicolaou test) without pathological findings (i.e. &lt; III) obtained&#xD;
             no longer than 12 months prior to screening visit&#xD;
&#xD;
          -  In addition subjects need to fulfil the following criterion in order to be randomized&#xD;
             (i.e. to enter the treatment period):&#xD;
&#xD;
               -  A minimum of 50 moderate to severe VMS episodes over the last 7 consecutive days&#xD;
                  prior to the baseline visit, as documented in the patient diary.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of any hormone replacement therapy (including phytoestrogens and other&#xD;
             plant-derived sex hormones) during the previous 12 weeks prior to screening&#xD;
&#xD;
          -  Ongoing or suspicion of any estrogen-dependent malignancy.&#xD;
&#xD;
          -  Endometrial thickness ≥ 5 mm at screening visit&#xD;
&#xD;
          -  Any history or current presence or suspicion of breast cancer, including carcinoma in&#xD;
             situ and other pre-cancerous conditions&#xD;
&#xD;
          -  Active malignant disease of any organ system (except for basal localized basal cell&#xD;
             carcinoma of the skin) or history thereof in the last 5 years prior to screening visit&#xD;
&#xD;
          -  Vaginal bleeding due to unidentified reason within 6 weeks prior to screening&#xD;
&#xD;
          -  Ongoing venous thromboembolic event or history thereof within 12 months prior to&#xD;
             screening visit&#xD;
&#xD;
          -  Known severe renal insufficiency (defined as glomerular filtration rate, GFR &lt; 30&#xD;
             mg/min/1.73 m²) at screening visit&#xD;
&#xD;
          -  Known lipid metabolism disturbances of genetic origin (e.g. familial&#xD;
             hypercholesterolemia, familial hypertriglyceridemia)&#xD;
&#xD;
          -  Acute or chronic liver diseases or a history of liver disease with liver enzymes&#xD;
             having not normalized since then&#xD;
&#xD;
          -  Severe disturbances of hepatic function (including porphyria), hepatic tumors, also in&#xD;
             medical history&#xD;
&#xD;
          -  Rotor syndrome or Dubin-Johnson syndrome&#xD;
&#xD;
          -  History of icterus or generalized pruritus during a previous pregnancy&#xD;
&#xD;
          -  History of myocardial infarction, stroke or transient ischemic attack or severe&#xD;
             cardiac disease, including symptomatic chronic heart failure&#xD;
&#xD;
          -  Ongoing major depression&#xD;
&#xD;
          -  Subjects who currently take or are planned to commence treatment with SSRI, SNRI for&#xD;
             any reason during the course of the study&#xD;
&#xD;
          -  Diabetes mellitus&#xD;
&#xD;
          -  Hypersensitivity to progesterone or excipients (e.g. soy) of the study medication&#xD;
&#xD;
          -  Medical history of HIV infection&#xD;
&#xD;
          -  Concomitant diseases or therapies that may cause VMS or affect VMS frequency or&#xD;
             severity, e.g. but not limited to poorly controlled thyroid dysfunction (thyroid&#xD;
             medication should be stable for at least 12 weeks prior to screening and TSH levels&#xD;
             should be within range), fear disorders (e.g. panic disorders)&#xD;
&#xD;
          -  Participation in a clinical trial or intake of any investigational medicinal product&#xD;
             within three months prior to screening visit&#xD;
&#xD;
          -  Previous participation in this clinical trial&#xD;
&#xD;
          -  Known or suspected drug or alcohol abuse&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Head of Clinical Development, PhD</last_name>
    <role>Study Director</role>
    <affiliation>BESINS Healthcare Ireland Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fachärztin für Gynäkologie und Geburtshilfe</name>
      <address>
        <city>Bernburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>June 21, 2017</study_first_submitted>
  <study_first_submitted_qc>June 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2017</study_first_posted>
  <last_update_submitted>March 5, 2019</last_update_submitted>
  <last_update_submitted_qc>March 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

